Despoina Pervizou, Joanna De Chiara, Lionel Spinelli, Maïa Nestor-Martin, Lionel Chasson, Kateryna Len-Tayon, Darya Yanushko, Frédéric Fiore, Marc Bajénoff, Bernard Malissen, Daniel Metzger, Gilles Laverny, Sandrine Henri
{"title":"健康小鼠前列腺和前列腺癌进展过程中免疫景观的特征","authors":"Despoina Pervizou, Joanna De Chiara, Lionel Spinelli, Maïa Nestor-Martin, Lionel Chasson, Kateryna Len-Tayon, Darya Yanushko, Frédéric Fiore, Marc Bajénoff, Bernard Malissen, Daniel Metzger, Gilles Laverny, Sandrine Henri","doi":"10.1080/2162402X.2025.2562220","DOIUrl":null,"url":null,"abstract":"<p><p>The immune landscape of healthy prostate and its alterations during prostate cancer (PCa) progression remain poorly characterized. Using scRNA-sequencing and multiparametric flow-cytometry analysis, we comprehensively characterized immune cells in wild-type and PTEN<sup>(i)pe-/-</sup> mouse prostates, a model that closely recapitulates human PCa. PCa in PTEN<sup>(i)pe-/-</sup> is marked by the recruitment of tumor-associated neutrophils (TANs), which represent the dominant immune cell population and resolved into eight distinct states, Trem2<sup>+</sup> tumor-associated-macrophages (TAMs), and exhausted CD8<sup>+</sup> T cells. Trem2<sup>+</sup> TAMs differ from the three main resident macrophage populations in the healthy prostate, exhibiting a strong metabolic and immunosuppressive signature, likely driven by the MIF/HIF1A-signaling axis. This study provides the first detailed characterization of immune cells in the healthy mouse prostate and reveals changes in the immune landscape associated with prostate cancer progression.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"14 1","pages":"2562220"},"PeriodicalIF":6.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477881/pdf/","citationCount":"0","resultStr":"{\"title\":\"Characterization of the immune landscape in healthy mouse prostate and during prostate cancer progression.\",\"authors\":\"Despoina Pervizou, Joanna De Chiara, Lionel Spinelli, Maïa Nestor-Martin, Lionel Chasson, Kateryna Len-Tayon, Darya Yanushko, Frédéric Fiore, Marc Bajénoff, Bernard Malissen, Daniel Metzger, Gilles Laverny, Sandrine Henri\",\"doi\":\"10.1080/2162402X.2025.2562220\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The immune landscape of healthy prostate and its alterations during prostate cancer (PCa) progression remain poorly characterized. Using scRNA-sequencing and multiparametric flow-cytometry analysis, we comprehensively characterized immune cells in wild-type and PTEN<sup>(i)pe-/-</sup> mouse prostates, a model that closely recapitulates human PCa. PCa in PTEN<sup>(i)pe-/-</sup> is marked by the recruitment of tumor-associated neutrophils (TANs), which represent the dominant immune cell population and resolved into eight distinct states, Trem2<sup>+</sup> tumor-associated-macrophages (TAMs), and exhausted CD8<sup>+</sup> T cells. Trem2<sup>+</sup> TAMs differ from the three main resident macrophage populations in the healthy prostate, exhibiting a strong metabolic and immunosuppressive signature, likely driven by the MIF/HIF1A-signaling axis. This study provides the first detailed characterization of immune cells in the healthy mouse prostate and reveals changes in the immune landscape associated with prostate cancer progression.</p>\",\"PeriodicalId\":48714,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":\"14 1\",\"pages\":\"2562220\"},\"PeriodicalIF\":6.5000,\"publicationDate\":\"2025-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477881/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402X.2025.2562220\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2025.2562220","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Characterization of the immune landscape in healthy mouse prostate and during prostate cancer progression.
The immune landscape of healthy prostate and its alterations during prostate cancer (PCa) progression remain poorly characterized. Using scRNA-sequencing and multiparametric flow-cytometry analysis, we comprehensively characterized immune cells in wild-type and PTEN(i)pe-/- mouse prostates, a model that closely recapitulates human PCa. PCa in PTEN(i)pe-/- is marked by the recruitment of tumor-associated neutrophils (TANs), which represent the dominant immune cell population and resolved into eight distinct states, Trem2+ tumor-associated-macrophages (TAMs), and exhausted CD8+ T cells. Trem2+ TAMs differ from the three main resident macrophage populations in the healthy prostate, exhibiting a strong metabolic and immunosuppressive signature, likely driven by the MIF/HIF1A-signaling axis. This study provides the first detailed characterization of immune cells in the healthy mouse prostate and reveals changes in the immune landscape associated with prostate cancer progression.
期刊介绍:
OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy.
As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology.
The journal covers a wide range of topics, including:
-Basic and translational studies in immunology of both solid and hematological malignancies
-Inflammation, innate and acquired immune responses against cancer
-Mechanisms of cancer immunoediting and immune evasion
-Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells
-Immunological effects of conventional anticancer therapies.